AMCP sends letter of concern for needed provisions in the Senate amendment in the nature of a substitute of H.R. 6 to Senate leadership and the Chairs and Ranking Members of HELP, Finance, Judiciary, and Commerce committees
AMCP webinar that detailed the Trump Administration’s American Patients First proposal for addressing the rising cost of pharmaceuticals.
AMCP webinar that detailed the Trump Administration’s American Patients First proposal for addressing the rising cost of pharmaceuticals.
On April 2, 2018 CMS released the Final CY 2019 Call Letter for Medicare Advantage (MA) and Medicare Part D Plans. There were no substantial changes to the proposals included in the Draft Call Letter, which were finalized generally as proposed. The agency did update the Standard Benefit Parameters to reflect the changes to the coverage gap that were included in the Bipartisan Budget Act of 2018.
AMCP CEO Blog: One of AMCP’s key strategic pillars is to advocate for legislation that will help advance the profession of managed care pharmacy. This function is on full display this week during our Annual Legislative Days event.
On March 5, 2018, AMCP provided comments in response to the Advance Summary of Methodological Changes for Calendar Year (CY) 2018 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2018 Call Letter. AMCP comments focus on the sections of the notice related to CMS's proposal on several new strategies for identifying potential opioid abuse.
On February 1, 2018, CMS released its 2019 Draft Call Letter. AMCP prepared in initial summary of the highlights contained in the Draft Call Letter. Of particular interest to AMCP members, CMS proposed new strategies for identifying potential opioid abuse which will work with the proposed codification of the current Opioid Monitoring System (OMS) under the Comprehensive Addiction and Recovery Act of 2015 (CARA).
AMCP submitted comments to CMS in response to its proposed rule for technical changes to the Medicare Prescription Drug Benefit Program. AMCP offered comments on the following areas of the proposed rule: drug management programs, Medication Therapy Management, benefit design & utilization management, health information technology & data interoperability, and fraud, waste, & abuse.
